Treatment of Aplastic Anemia with Cyclosporine and ATG
Introduction to Treatment Protocols
- The American College of Oncology recommends horse anti-thymocyte globulin (ATG) at 40 mg/kg/day for 4 days and cyclosporine at 5 mg/kg/day divided into two doses for treating aplastic anemia 1
ATG and Cyclosporine Dosing
- The standard dosing protocol for horse ATG is 40 mg/kg/day for 4 days, with a total dose of 160 mg/kg, as recommended by the Journal of Hematology and Oncology 2
- The initial dose of cyclosporine should be 5 mg/kg/day divided into two equal doses, according to the Annals of Oncology 1
Monitoring and Management
- Blood pressure measurement should be performed at each visit, along with serum creatinine, complete blood count, liver function tests, potassium, and lipid levels, as suggested by Praxis Medical Insights 3
- The dose of cyclosporine should be adjusted based on blood levels and renal function, with a reduction of 25-50% if serum creatinine increases >30% above baseline, as recommended by Praxis Medical Insights 3
- For patients experiencing nephrotoxicity, the cyclosporine dose should be reduced by 25-50% if serum creatinine increases >30% above baseline, according to Praxis Medical Insights 3
- For patients with hypertension, the cyclosporine dose should be decreased and calcium channel blockers considered if needed, as suggested by Praxis Medical Insights 3
Side Effects and Management
- Cyclosporine-related side effects include hypertension, nephrotoxicity, hirsutism, and gum hypertrophy, as reported in Kidney International 4
Combination Therapy
- For HLA-matched sibling transplantation, the Cy-ATG regimen consists of cyclophosphamide 200 mg/kg total dose and ATG 11.25-15 mg/kg, as recommended by the Journal of Hematology and Oncology 2
- For unrelated donor transplantation, the FluCy-ATG regimen includes fludarabine 120 mg/m², cyclophosphamide 120 mg/kg, and ATG 11.25-15 mg/kg, according to the Journal of Hematology and Oncology 2
- For haploidentical transplantation, the mBuCyFluATG regimen consists of busulfan 6.4 mg/kg IV, fludarabine 120 mg/m², cyclophosphamide 200 mg/kg, and ATG 10 mg/kg or ATG-F 20 mg/kg, as recommended by the Journal of Hematology and Oncology 2
Aplastic Anemia Treatment Guidelines
Immunosuppressive Therapy
- Equine ATG has demonstrated superior efficacy compared to rabbit-derived ATG in aplastic anemia, though rabbit ATG is approved only for renal transplant rejection 5
- The American Thoracic Society recommends monitoring for pulmonary edema and systemic inflammatory response syndrome during ATG infusion, as well as daily CBC monitoring during initiation, with subsequent intervals based on clinical response 5
- The use of ATG is associated with serum sickness, which may cause acute renal dysfunction in approximately 10% of patients, and major adverse reactions such as anaphylaxis, dyspnea, hemolysis, leukopenia, thrombocytopenia, and sepsis 5
- Infection prophylaxis for Pneumocystis pneumonia should be considered in all patients receiving ATG 5
Conditioning Regimens for Transplantation
- The European Society for Medical Oncology recommends an HLA-matched sibling transplantation regimen consisting of cyclophosphamide 200 mg/kg total dose plus ATG 11.25-15 mg/kg (Cy-ATG regimen) 6
- For unrelated donor transplantation, a regimen of fludarabine 120 mg/m², cyclophosphamide 120 mg/kg, and ATG 11.25-15 mg/kg (FluCy-ATG regimen) is recommended 6
- Haploidentical transplantation may use a regimen of busulfan 6.4 mg/kg IV, fludarabine 120 mg/m², cyclophosphamide 200 mg/kg, and ATG 10 mg/kg or ATG-F 20 mg/kg (mBuCyFluATG regimen) 6